Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

cofhu12twits Sep. 12 at 7:30 PM

$GUTS Added 10k just now

0 · Reply

willyield Sep. 12 at 6:13 PM

$GUTS

0 · Reply

DSAdsdsas Sep. 12 at 1:44 PM

$GUTS The most important thing at this point is the three-month midpoint clinical results. I'd like to believe the company's recent board expansion stems from its confidence in the internal data supporting those results.

0 · Reply

alphaonetrading Sep. 12 at 11:12 AM

$GUTS Fractyl Health, Inc. (NASDAQ: GUTS) reported $22.3 million in cash as of June 30, 2025, down from $67.5 million at year-end 2024, driven by R&D and clinical costs. Q2 2025 cash burn dropped to $19.8 million from $25.4 million in Q1. An August 2025 public offering raised ~$20.7 million net proceeds. With ~$27 million in cash and a ~$6.6 million monthly burn rate, the runway extends about four months from September 12, 2025, to mid-January 2026, covering REMAIN-1 study readouts. Positive September 2025 data could prompt a follow-on offering to extend the runway further. Additional financing may still be needed.

1 · Reply

alphaonetrading Sep. 12 at 11:01 AM

$GUTS Fractyl Health’s gene therapy platform, Rejuva, is an adeno-associated virus (AAV)-based approach designed to deliver pancreatic genes to treat type 2 diabetes (T2D) and obesity. It aims to provide a one-time, targeted administration to the pancreas, promoting durable remission by enhancing insulin production and improving metabolic regulation. The therapy seeks to restore pancreatic function and address root causes like insulin resistance, potentially reducing or eliminating the need for ongoing drug treatments. Preclinical data in animal models (e.g., db/db mice) showed a single dose prevented weight gain and hyperglycemia, with sustained benefits. Human Phase 1/2 dosing is planned for 2026 in Europe, with initial data expected that year, pending regulatory clearance.

0 · Reply

Stmkr Sep. 12 at 8:57 AM

$GUTS This one seems very undervalued. With huge binary catalysts the next few months and potential submission for approval by the end of 2026. If not for the terrible offering in August I would be very bullish. Any concerns about the science/data?? 3 month data from Revael and 2-year data from the German cohort seem very convincing to me. The market is huge and the procedure relatively simple and can be inocrporated in endoscopies conducted anyway in a large number of these patients. / Their gene therapy (first data in 2026) also looks very interesting. What am I missing?

1 · Reply

alphaonetrading Sep. 12 at 1:18 AM

$GUTS Positive REMAIN-1 data and 30% dilution (225M shares) suggest a $4 target price. Assuming positive REMAIN-1 trial data in September 2025, a DCF valuation with 225 million fully diluted shares (30% dilution) projects a $4 share price by October 2025. This reflects a $175 billion TAM with ~1% penetration, a 12% discount rate, 80% success probability, 40% net margins, and no terminal growth beyond 2040, implying a ~$900 million market cap. The conservative $4 target balances high reward against regulatory and execution risks

1 · Reply

alphaonetrading Sep. 12 at 12:48 AM

$GUTS 3. Total Outstanding Shares with Full Dilution Basic shares outstanding (92.73 million) + Dilutive shares (49.31 million) = 142.04 million shares.

0 · Reply

alphaonetrading Sep. 11 at 10:14 PM

$GUTS Fractyl Health’slead product, Revita®, is an outpatient endoscopic procedure designed to treat obesity and type 2 diabetes by addressing insulin resistance and weight regain. It targets the duodenum, the upper small intestine, where a dysfunctional mucosal lining can impair metabolic signaling, contributing to these conditions. Revita uses a proprietary catheter to deliver controlled hydrothermal ablation, resurfacing the duodenal lining to restore healthy tissue and improve glucose regulation and satiety signaling. This aims to sustain weight loss, especially for patients discontinuing GLP-1 drugs, where 70-80% regain weight. The procedure takes about an hour, requires no incisions, and has FDA Breakthrough Device Designation. Clinical trials, like REMAIN-1, show promise in maintaining weight loss post-GLP-1. Fractyl’s preclinical Rejuva® complements Revita, exploring gene therapy for long-term metabolic benefits, targeting a $100B+ market for obesity solutions.

1 · Reply

alphaonetrading Sep. 11 at 10:10 PM

$GUTS likely to double Sept data catalyst is close, high-profile obesity market buzzing. Could hit $2+ in 1-2 wks if data lands. Both high-risk: 100-500% upside or 50% drop .

0 · Reply

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Sep 3, 2025, 7:00 AM EDT - 10 days ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Aug 12, 2025, 8:00 PM EDT - 4 weeks ago

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 weeks ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 5 weeks ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 5 weeks ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 5 weeks ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 5 weeks ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 5 weeks ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jul 16, 2025, 10:13 AM EDT - 2 months ago

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 2 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 2 months ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 4 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 4 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 4 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 4 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 4 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 6 months ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 6 months ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 7 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 8 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 9 months ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 9 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 10 months ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 10 months ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 10 months ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 11 months ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 11 months ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 11 months ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates

Jun 23, 2024, 1:30 PM EDT - 1 year ago

Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's

May 20, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024

May 13, 2024, 10:37 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:00 PM EDT - 1 year ago

Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates

May 13, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)

May 8, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

May 7, 2024, 6:00 AM EDT - 1 year ago

Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024

cofhu12twits Sep. 12 at 7:30 PM

$GUTS Added 10k just now

0 · Reply

willyield Sep. 12 at 6:13 PM

$GUTS

0 · Reply

DSAdsdsas Sep. 12 at 1:44 PM

0 · Reply

alphaonetrading Sep. 12 at 11:12 AM

1 · Reply

alphaonetrading Sep. 12 at 11:01 AM

0 · Reply

Stmkr Sep. 12 at 8:57 AM

1 · Reply

alphaonetrading Sep. 12 at 1:18 AM

1 · Reply

alphaonetrading Sep. 12 at 12:48 AM

$GUTS 3. Total Outstanding Shares with Full Dilution Basic shares outstanding (92.73 million) + Dilutive shares (49.31 million) = 142.04 million shares.

0 · Reply

alphaonetrading Sep. 11 at 10:14 PM

1 · Reply

alphaonetrading Sep. 11 at 10:10 PM

$GUTS likely to double Sept data catalyst is close, high-profile obesity market buzzing. Could hit $2+ in 1-2 wks if data lands. Both high-risk: 100-500% upside or 50% drop .

0 · Reply

willyield Sep. 11 at 9:52 PM

$GUTS

0 · Reply

BioRich Sep. 11 at 5:28 PM

$GUTS I truly believe $GUTS is about to explode. So many stars aligning for the data pop. I truly believe lucrative PS follows. Think Fractyl leadership love their product too much to let it just go to BP so I'd be surprised if they sell. #1 On my BO/PS board though. I feel a deal is done, just waiting on data release any day. Congrats Longs! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $SPY $XBI

1 · Reply

robbrenner2 Sep. 11 at 4:11 PM

$YAAS The Scalpers and Shorts have a stranglehold on this one. Just like they do on $GUTS. We'll be here for a while as long as the Scalpers and Shorts are here making bank.

1 · Reply

Kevin73ca Sep. 10 at 6:12 PM

$AGMH $GUTS bought big qty More on the way

0 · Reply

Kevin73ca Sep. 10 at 6:10 PM

$AGMH $GUTS may be after market run

0 · Reply

Kevin73ca Sep. 10 at 6:10 PM

$AGMH watch $GUTS

0 · Reply

BioRich Sep. 9 at 7:56 PM

$GUTS Huge Industry Leaders added to Fractyl's Board of Directors. More to follow. This is a big deal though. It's starting to walk it out so perfect time to lock it in under a buck. https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-expands-board-directors-appointments-industry

1 · Reply

willyield Sep. 9 at 5:25 PM

$GUTS

0 · Reply

BioRich Sep. 8 at 7:03 PM

$VVOS $GUTS $GSAT $JMIA $BHVN on our "Worth a Look" list. All have tremendous upside. Some have started to move. Some have pulled back. Some are sitting on potentially monumental news. Each worth a look IMHO. Let me know your thoughts! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we learn and find these gems. Let's make some money. Cheers!

0 · Reply

Mike__Hawk Sep. 8 at 1:35 PM

$GUTS so will the reverse split be 5-1 or 10-1 here?

1 · Reply

willyield Sep. 5 at 1:56 PM

$GUTS

0 · Reply

elmono Sep. 4 at 7:49 PM

$GUTS pure junk 😂👇

0 · Reply

Market Cap	51.30M
Revenue (ttm)	90,000.00
Net Income (ttm)	-68.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76,322.22%
Debt to Equity Ratio	-1.65

Volume	1,678,600
Avg Vol	821,226
Day's Range	N/A - N/A
Shares Out	50.29M
Stochastic %K	70%
Beta	1.55
Analysts	Strong Sell
Price Target	$5.90